Latest Pharma Insights
Sanofi Snaps Up Dynavax For $2.2bn In Vaccine Business Push
The deal would add Dynavax’s marketed adult hepatitis B vaccine and an early-stage shingles candidate to Sanofi's roster of immunization products.
Scrip - December 24, 2025
The deal would add Dynavax’s marketed adult hepatitis B vaccine and an early-stage shingles candidate to Sanofi's roster of immunization products.
Scrip - December 24, 2025
FDA Is Bearer Of Bad Tidings For Sanofi’s Tolebrutinib
The Paris-headquartered firm has been hit with a complete response letter for its oral BTK inhibitor, quite a shock given that it was not expecting to hear from the US agency on its application for the multiple sclerosis drug until early next year.
Scrip - December 24, 2025
The Paris-headquartered firm has been hit with a complete response letter for its oral BTK inhibitor, quite a shock given that it was not expecting to hear from the US agency on its application for the multiple sclerosis drug until early next year.
Scrip - December 24, 2025
Sanofi Snaps Up Dynavax For $2.2bn In Vaccine Business Push
The deal would add Dynavax’s marketed adult hepatitis B vaccine and an early-stage shingles candidate to Sanofi's roster of immunization products.
Scrip - December 24, 2025
The deal would add Dynavax’s marketed adult hepatitis B vaccine and an early-stage shingles candidate to Sanofi's roster of immunization products.
Scrip - December 24, 2025
FDA Is Bearer Of Bad Tidings For Sanofi’s Tolebrutinib
The Paris-headquartered firm has been hit with a complete response letter for its oral BTK inhibitor, quite a shock given that it was not expecting to hear from the US agency on its application for the multiple sclerosis drug until early next year.
Scrip - December 24, 2025
The Paris-headquartered firm has been hit with a complete response letter for its oral BTK inhibitor, quite a shock given that it was not expecting to hear from the US agency on its application for the multiple sclerosis drug until early next year.
Scrip - December 24, 2025
Infographic: Ireland’s Medtech Industry, By The Numbers
Ireland's medtech ecosystem continues to flourish, with more than 50,000 employees across 700 companies. The sector set a venture capital record in 2024 and is on pace to match or exceed it this year.
Medtech Insight - December 22, 2025
Ireland's medtech ecosystem continues to flourish, with more than 50,000 employees across 700 companies. The sector set a venture capital record in 2024 and is on pace to match or exceed it this year.
Medtech Insight - December 22, 2025
‘Innovating For Our Customers’ Needs’ Is Focus For Philips’ Bert van Meurs
During his 40 years at Royal Philips, Bert van Meurs has seen the medical devices business grow in line with the evolving needs of healthcare providers with whom the company partners in customer and patient focused innovation.
Medtech Insight - December 22, 2025
During his 40 years at Royal Philips, Bert van Meurs has seen the medical devices business grow in line with the evolving needs of healthcare providers with whom the company partners in customer and patient focused innovation.
Medtech Insight - December 22, 2025
UK Perspective: Where 2025 Was About Promise, 2026 Will Be About Execution
A forward-looking view of prospects for regulatory and market access improvement from the UK’s biggest medtech industry lobby group, the Association of British HealthTech Industries (ABHI).
Medtech Insight - December 22, 2025
A forward-looking view of prospects for regulatory and market access improvement from the UK’s biggest medtech industry lobby group, the Association of British HealthTech Industries (ABHI).
Medtech Insight - December 22, 2025
French Finance Bill Expected To Bring Increased Burden For Pharma
The French national assembly has adopted a version of the 2026 social security finance bill that includes price cuts and penalties for companies that adopt tactics to delay generic entry.
Pink Sheet - December 22, 2025
The French national assembly has adopted a version of the 2026 social security finance bill that includes price cuts and penalties for companies that adopt tactics to delay generic entry.
Pink Sheet - December 22, 2025
GlucoModicum’s Needle-Free Sofio Could Offer Alternative CGM Approach
The system combines a durable rechargeable transmitter with a two-year life span and a replaceable single-day sensor. The product is intended to address pain, inconvenience and adherence challenges associated with multiweek CGM use.
Medtech Insight - December 22, 2025
The system combines a durable rechargeable transmitter with a two-year life span and a replaceable single-day sensor. The product is intended to address pain, inconvenience and adherence challenges associated with multiweek CGM use.
Medtech Insight - December 22, 2025
Coty Shakeup: P&G Veteran Strobel Replaces Nabi
Coty Inc. has appointed longtime Procter & Gamble executive Markus Strobel as executive chairman and interim CEO following Sue Nabi’s five-year tenure, as the company undertakes a strategic review and navigates a period of transition in its global beauty business.
HBW Insight - December 23, 2025
Coty Inc. has appointed longtime Procter & Gamble executive Markus Strobel as executive chairman and interim CEO following Sue Nabi’s five-year tenure, as the company undertakes a strategic review and navigates a period of transition in its global beauty business.
HBW Insight - December 23, 2025
Alvotech Sees Out 2025 With Simponi Biosimilar Debut In Europe
Alvotech and marketing partner Advanz Pharma have claimed a first with the launch of their Gobivaz golimumab biosimilar rival to Simponi in Europe.
Generics Bulletin - December 22, 2025
Alvotech and marketing partner Advanz Pharma have claimed a first with the launch of their Gobivaz golimumab biosimilar rival to Simponi in Europe.
Generics Bulletin - December 22, 2025
BsUFA IV: Approval Criteria Shift May Mean US FDA User Fee Changes
A Teva official suggested the increasing reliance on analytical characterizations rather than clinical studies to show biosimilarity should warrant user fee structure changes.
Generics Bulletin - December 22, 2025
A Teva official suggested the increasing reliance on analytical characterizations rather than clinical studies to show biosimilarity should warrant user fee structure changes.
Generics Bulletin - December 22, 2025
Biocon Strikes Aflibercept Deal And Launches Liraglutide In Europe
Biocon Biologics has announced a further settlement over Eylea (aflibercept) allowing launch of its Yesafili biosimilar in territories outside of the US and Canada early next year. Meanwhile, Biocon Limited has launched its liraglutide rival to Victoza and Saxenda in the Netherlands.
Generics Bulletin - December 22, 2025
Biocon Biologics has announced a further settlement over Eylea (aflibercept) allowing launch of its Yesafili biosimilar in territories outside of the US and Canada early next year. Meanwhile, Biocon Limited has launched its liraglutide rival to Victoza and Saxenda in the Netherlands.
Generics Bulletin - December 22, 2025
Europe Leads Charge As Private Equity Roars Back Into Off-Patent Pharma
A pair of private equity mega-deals dominated the mergers and acquisitions landscape in 2025, but there was still a clear appetite for smaller, strategic takeovers and tuck-ins across the generics, biosimilars, and off-patent medicines field.
Generics Bulletin - December 22, 2025
A pair of private equity mega-deals dominated the mergers and acquisitions landscape in 2025, but there was still a clear appetite for smaller, strategic takeovers and tuck-ins across the generics, biosimilars, and off-patent medicines field.
Generics Bulletin - December 22, 2025
Podcast: “We Are On The Cusp Of A Real Revolution”: OHC Rare Disease Center Boosts Innovation
Matthew Wood, director and chief scientific officer at Oxford-Harrington Rare Disease Center, discusses the state of rare disease R&D, the evolving landscape of genomics and genetic therapies, and the challenges around the biopharma industry’s narrow focus on only 5-10% of rare diseases.
In Vivo - December 22, 2025
Matthew Wood, director and chief scientific officer at Oxford-Harrington Rare Disease Center, discusses the state of rare disease R&D, the evolving landscape of genomics and genetic therapies, and the challenges around the biopharma industry’s narrow focus on only 5-10% of rare diseases.
In Vivo - December 22, 2025
Topadur Sees Future Expansion From Wound Healing Into Longevity
A new CEO, a passionate founder, early-stage R&D and hopes of an IPO – can Swiss biotech Topadur find success?
In Vivo - December 22, 2025
A new CEO, a passionate founder, early-stage R&D and hopes of an IPO – can Swiss biotech Topadur find success?
In Vivo - December 22, 2025
How MFN And IRP Convergence Are Rewriting Biotech’s Playbook
Biotech’s pricing playbook is being upended as US Most-Favored Nation rules collide with Europe’s evolving International Reference Pricing models. The result: launch strategies, deal structures and innovation pipelines are all under pressure.
In Vivo - December 22, 2025
Biotech’s pricing playbook is being upended as US Most-Favored Nation rules collide with Europe’s evolving International Reference Pricing models. The result: launch strategies, deal structures and innovation pipelines are all under pressure.
In Vivo - December 22, 2025
Cell And Gene Therapy Leaders See Transformative Results Outweighing Industry Setbacks
Executives at the cell and gene therapy accelerator ElevateBio point to clinical impact, expanding toolbox and manufacturing improvements as reasons for optimism.
In Vivo - December 22, 2025
Executives at the cell and gene therapy accelerator ElevateBio point to clinical impact, expanding toolbox and manufacturing improvements as reasons for optimism.
In Vivo - December 22, 2025